Navigation Links
New Anal Cancer Therapy Fails to Improve Outcomes
Date:4/22/2008

Experimental use of cisplatin no better than standard treatment, researchers say

TUESDAY, April 22 (HealthDay News) -- Compared to the standard treatment regimen for anal canal cancer, the use of the chemotherapy drug cisplatin before other treatments didn't improve disease-free survival and resulted in a higher rate of colostomy procedures, says a U.S. study.

Currently, the preferred primary therapy for patients with anal canal cancer is chemoradiation (concurrent use of radiation and the anti-cancer drugs fluorouracil/mitomycin), which achieves a five-year survival rate of about 65 percent, according to background information in the study.

It's been suggested that reducing cancer in the primary tumor and in the lymph node or nodes prior to chemoradiation might improve disease-free survival. Pilot studies using cisplatin prior to chemoradiation showed promise.

In this new, randomized controlled trial, Dr. Jaffer A. Ajani, of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues compared treatment with fluorouracil plus mitomycin and radiation therapy to treatment with fluorouracil plus cisplatin and radiation therapy.

The findings from 644 patients showed a five-year, disease-free survival rate of 60 percent in the mitomycin group and 54 percent in the cisplatin group. The five-year overall survival rate was 75 percent in the mitomycin group and 70 percent in the cisplatin group. There were more cancer-related deaths in the cisplatin group (54) than in the mitomycin group (28).

The five-year, local-regional cancer recurrence and distant metastasis rates were 25 percent and 15 percent, respectively, for the mitomycin group and 33 percent and 19 percent, respectively, for the cisplatin group. Severe blood toxicity was worse in the mitomycin group. The cisplatin group had a higher rate of colostomy (19 percent vs. 10 percent).

"The question remains how to further improve disease-free and colostomy-free survival relative to the continued standard of concurrent chemoradiation with fluorouracil and mitomycin," the study authors wrote. "Options to explore included targeted agents (e.g., results with concurrent cetuximab plus radiation for head/neck cancer), dose escalation with intensity-modulated radiation plus concurrent chemotherapy, and surgical excision of residual cancer after concurrent chemoradiation at an earlier interval, when sphincter preservation may still be feasible in select patients."

The study was published in this week's issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about anal cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, April 22, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists discover a mechanism that can send cells on the road to cancer
2. Factors in Cancer Death Rates Stay Stagnant
3. Cancer Death Rates Stay Stagnant
4. OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
5. Phone counseling improves quality of life, immune systems of cervical cancer survivors
6. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
7. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
8. Potential viral therapy weapon for difficult cancers is safe and effective in study
9. American Cancer Society report details cancer prevention efforts
10. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
11. Cancer cells spread by releasing bubbles, according to an MUHC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... , ... Providing broad access to life-saving drugs and rewarding the innovators who ... to address this problem. , That was the message from Dana Goldman, PhD, Leonard ... University of Southern California, who served as the keynote speaker for Western University of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke ... young adults, has kicked off its 4th annual Forum for Innovative Treatment Solutions ... is “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ 2017 ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t ... the next project in the company’s esteemed VISION House demonstration project series. Manifesting the ... the amount of resources they need to live affordably and abundantly without unduly taxing ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover Symmetry , ... , an active lifestyle company that provides Human Performance Training and education to ... offers, first responders, military officers and others in service through the development and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical ... Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual ... healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, share ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Executive Officer of the Company is scheduled to present on Tuesday, ... and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: